Anorak

Anorak News | UK Government profits from Canadian cannabis smokers

UK Government profits from Canadian cannabis smokers

by | 6th, August 2019

cannabis uk

At what point does the Government accept defeat in the war on cannabis? Glasgow food safety business R-Biopharm Rhône (RBR), a subsidiary of German parent company R-Biopharm, will supply test kits to a Canadian cannabis producer. The weed grower wants to rid their products of carcinogenic toxins. RBR makes kits that test for toxins in milk, spices, cereals and animal feeds. So why not put its skills to profit from the booming marijuana industry? Cannabis is legal in Canada. In the UK the law allows some medical use of the drug.

So here’s a renowned business based in the UK making money from weed. R-Biopharm Rhône product manager Claire Milligan tells the Herald: “Just like any other ingestible item, strict consumer protection legislation requires that cannabis products, including oils, cookies and cannabis plants themselves, should be tested for the presence of dangerous toxins. While the legality of cannabis products in the UK is currently the subject of wide-ranging debate, in those jurisdictions, such as Canada, certain states in the US, Spain, Portugal and the Netherlands where consumption of cannabis products is permitted, testing for toxins remains of great importance. In the wake of the sale to our Canadian customer we anticipate further demand for our test kits in other regions where consumption of cannabis is legal as well as perhaps, at some stage, here in the UK.”

How do we feel about the UK doing business with companies whose produce is banned here? Any reputable British firm, which RBR certainly is, will pay taxes into the Treasury’s coffers. Some of that money will surely come from the Canada deal. Isn’t it a tad hypocritical of the UK Government to profit from the consumption of cannabis for non-medical use – the same drug it bans and arrests people for selling? How ethical is that?



Posted: 6th, August 2019 | In: Key Posts, News, The Consumer Comment | TrackBack | Permalink